M&A

Sales & Marketing

The diagnostics and life sciences tools sector is attracting continued investor interest across both private equity and large corporates.

News

Tarsus agrees to buy Alkeus in an $800m deal that will give it rights to a drug for eye disorder Stargardt disease with "blockbuster potential."

News

A media report suggests there is no substance to the rumours of a $400 billion mega-merger between AstraZeneca and Bristol Myers Squibb.

News

Two players in the radiopharma sector, Curium and Lantheus, have agreed to merge and create an end-to-end player in diagnostics and therapeutics.

News

Supernus Pharma and Indivior have signed an all-stock merger agreement that would establish a new CNS-focused company with annual sales of $2.2bn.

News

There are rumours that the first pharma 'mega-merger' for several years – between AstraZeneca and Bristol Myers Squibb – is under discussion.